eXoZymes provides an AI‑enhanced, cell‑free biomanufacturing platform that designs and produces engineered enzymes (exozymes) for continuous synthesis of high‑value natural products and complex chemicals. The system combines AI‑driven enzyme design, high‑throughput BioClick screening, and a cell‑free reactor with cofactor recycling to deliver stable, high‑purity enzymes at scale, reducing development time and capital costs for pharmaceutical, nutraceutical, and fragrance manufacturers.
Funding
Funding not disclosed
Founders
Product
Problem
Many high‑value natural products and complex chemicals are either too scarce, expensive to extract, or require toxic petrochemical processes, making them inaccessible for pharmaceutical, wellness, or industrial use. Traditional cell‑based biomanufacturing adds further constraints such as low yields, long development cycles, and high capital costs.
Solution
eXoZymes offers an AI‑enhanced, cell‑free biomanufacturing platform that designs and produces “exozymes” – engineered enzymes optimized to function outside living cells. By integrating AI‑driven enzyme design with high‑throughput synthesis and the BioClick screening workflow, the platform rapidly creates stable, high‑purity enzymes that catalyze target reactions in a cell‑free reactor. The process eliminates the scaling bottleneck of microbial production, enabling predictable, continuous synthesis of scarce molecules such as NCT, non‑intoxicating cannabinoid analogs, and santalene. The platform also embeds manufacturability early in discovery, shortening development timelines and reducing capital intensity. Commercialization pathways include spin‑outs, joint ventures, and licensing, allowing partners to bring products to market while eXoZymes remains capital‑light.
Target Audience
Primary customers are pharmaceutical and nutraceutical developers, fragrance manufacturers, and industrial partners seeking sustainable, scalable production of complex natural products.
Features
- AI‑augmented enzyme engineering that predicts stability and activity for cell‑free conditions, leveraging proprietary models beyond structure prediction
- BioClick high‑throughput screening platform for rapid iteration of enzyme variants using mass‑spectrometry‑based analysis
- Cell‑free bioreactor system with integrated cofactor recycling and process control for continuous high‑yield production
- Scalable purification and immobilization methods delivering high‑purity exozymes suitable for industrial use
- Flexible commercialization models (spin‑outs, joint ventures, licensing) to align with partner capabilities and market needs